



## Financial Tear Sheet

### Overview

Zogenix, Inc. (Nasdaq: ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.



### Recent News & Investor Events

08/08/17

Zogenix Provides Corporate Update and Reports Second Quarter 2017 Financial Results

08/01/17

Zogenix to Release Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 8

06/22/17

Zogenix Receives Orphan Drug Designation from FDA for ZX008 in Treatment of Lennox Gastaut Syndrome

There are currently no events scheduled.

### SEC Filings

Filing Date	Form	Description
09/22/17	8-K	Report of unscheduled material events or corporate event
09/11/17	SC 13G/A	An amendment to the SC 13G filing
08/09/17	SC 13G/A	An amendment to the SC 13G filing
08/08/17	10-Q	Quarterly report which provides a continuing view of a company's financial position